Intensive fundus screenings reduces need for enucleation

Article

Intensive fundus screening in retinoblastoma patients decreases the need for enucleation and external beam radiation (EBRT).

Intensive fundus screening in retinoblastoma patients decreases the need for enucleation and external beam radiation (EBRT), according to a study published in Eye.

The investigation, led by Dr P.R. Rothschild, Department of Ocular Oncology, Institut Curie, Paris, France, analysed the fundus examination results of 547 retinoblastoma patients between January 1995 and December 2004. Fundus exams were performed on children shortly after birth. All patients had a positive family history of retinoblastoma and underwent fundus screening under general anaesthesia.

Familial retinoblastoma cases were retrospectively placed into a 'screened' group and a 'non-screened' group (NS). The screened group were classified as intensively screened (IS) or non-intensively screened (NIS). The Fisher exact test was used to compare categorical variables between groups. The Kruskal-Wallis test was also used to compare continuous variables.

Of the 547 retinoblastoma patients included in the study, 59 were identified as familial cases. The NS group contained 20 patients, the S group consisted of 23 and the IS group had 16 patients.

The number of children who experienced enucleation was 13 for the NS group, 2 for the S group and 0 for the IS group. External beam radiation (EBRT) was completed in 6 of the NS children, 0 in the S group and 2 in the IS group.

Visual acuity and chemotherapy burden were not significantly different when compared between the groups. Intensive fundus screening reduced the need for enucleation and EBRT in children. The study recommends the referral of children with retinoblastoma for genetic counselling and sufficient fundus screening.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
© 2025 MJH Life Sciences

All rights reserved.